The influence of polymorphisms in the large group of MMP and TIMP genes on clinical outcomes in patients after ST elevation myocardial infarction (STEMI) treated with primary PCI was analysed. In total, 550 consecutive Caucasian patients with STEMI were included in the present study, with a median of 32 months. We analysed 19 polymorphisms in the genes coding MMP and TIMP genes. The MMP-1 -519A/G and -422A/T polymorphisms are associated with combined endpoint after myocardial infarction. The hazard ratio for AT variant of MMP-1 -422A/T was 1.75 (p < 0.001); the variants with at least one A allele of MMP-1 -519A/G have less risk of combined endpoint. The TT variants of -1562C/T MMP-9 and at least one T allele of +92C/T MMP-13 were considered in a trend to affect disease progression and long-term survival after myocardial infarction. According to reclassification analysis NRI and IDI, long-term risk stratification using MMP-1 -422A/T and -519A/G polymorphisms gives additional information to the commonly used GRACE risk score. Patient stratification after myocardial infraction (MI) according to risk genotypes of MMP-1 polymorphisms could have important clinical implications for identification of patients at risk and therapeutic strategies.

Cardiology Department Faculty Hospital Brno Brno Czech Republic

Cardiology Department University Hospital Brno Jihlavska 20 Brno 625 00 Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

Hospital Podlesi a s Trinec Czech Republic

Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic

International Clinical Research Center Department of Cardiovascular Disease University Hospital St Annes's Brno Czech Republic

See more in PubMed

Am Heart J. 2007 Oct;154(4):751-8 PubMed

Eur Heart J. 2003 Sep;24(18):1668-71 PubMed

Hum Genet. 1999 Nov;105(5):418-23 PubMed

Dis Markers. 2012;33(1):43-9 PubMed

Europace. 2007 Sep;9(9):724-9 PubMed

Mol Cell Probes. 2002 Feb;16(1):63-6 PubMed

Circulation. 1999 Apr 13;99(14 ):1788-94 PubMed

Matrix Biol. 2002 Oct;21(6):487-98 PubMed

Ann N Y Acad Sci. 2007 Sep;1110:166-76 PubMed

Physiol Rev. 2007 Oct;87(4):1285-342 PubMed

Hum Mol Genet. 2004 Nov 1;13(21):2659-69 PubMed

J Biol Chem. 1999 Jul 30;274(31):21491-4 PubMed

J Am Coll Cardiol. 1995 May;25(6):1263-72 PubMed

Eur Heart J. 2004 Apr;25(8):688-93 PubMed

Cancer Res. 1998 Dec 1;58(23):5321-5 PubMed

PLoS One. 2014 Sep 05;9(9):e106816 PubMed

Eur Heart J. 2007 Mar;28(6):711-8 PubMed

Eur J Cancer. 2011 Jan;47(1):107-15 PubMed

BMJ. 2006 Nov 25;333(7578):1091 PubMed

J Card Fail. 1999 Jun;5(2):117-26 PubMed

Circulation. 2015 Apr 7;131(14):1247-59 PubMed

Matrix Biol. 2004 Jan;22(7):585-91 PubMed

J Periodontol. 2006 Nov;77(11):1850-5 PubMed

Stem Cell Res Ther. 2014 Jan 24;5(1):14 PubMed

Bioinformatics. 2005 Jan 15;21(2):263-5 PubMed

Atherosclerosis. 2005 May;180(1):73-8 PubMed

J Mol Cell Cardiol. 2010 Mar;48(3):490-6 PubMed

J Card Fail. 2011 Feb;17(2):115-21 PubMed

Circ Res. 1992 May;70(5):1006-17 PubMed

Mol Hum Reprod. 2011 Oct;17(10):637-52 PubMed

PLoS Genet. 2014 Jul 31;10(7):e1004469 PubMed

Pharmacol Ther. 2009 Aug;123(2):255-78 PubMed

Eur Heart J. 2008 Sep;29(17):2116-24 PubMed

Life Sci. 2012 Oct 29;91(17-18):823-7 PubMed

Eur J Cardiothorac Surg. 2006 Oct;30(4):604-10 PubMed

PLoS One. 2016 Aug 23;11(8):e0161666 PubMed

Circulation. 2003 Apr 1;107(12):1579-85 PubMed

Gynecol Obstet Invest. 2001;52(2):124-7 PubMed

Circ Cardiovasc Imaging. 2014 Mar;7(2):292-302 PubMed